ArticleNon-coding RNA research2021
Differential non-coding RNAs expression profiles of invasive and non-invasive pituitary adenomas.
Article in Non-coding RNA research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.International journal of molecular sciences · 2023Pooled it
- MicroRNA Is Downregulated in Invasive Non-Functioning Pituitary Adenomas.International journal of molecular sciences · 2025Article
- Liquid Biopsy in Pituitary Neuroendocrine Tumors-Potential Biomarkers for Diagnosis, Prognosis, and Therapy.International journal of molecular sciences · 2025Review
- New approaches to targeted drug therapy of intracranial tumors.Cell death discovery · 2025Review
- The Expression Patterns of Non-Coding RNAs in Periodontal Disease.Dentistry journal · 2024Review
- lncRNA Biomarkers of Glioblastoma Multiforme.Biomedicines · 2024Review
- Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas.Current issues in molecular biology · 2024Review
- MiRNAs and lncRNAs in the regulation of innate immune signaling.Non-coding RNA research · 2023Review
- Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy.Cancers · 2023Review
- Regulation of long noncoding RNAs in the pathogenesis and clinical implications of pituitary adenomas.Immunity, inflammation and disease · 2023Review
- Cell-Free miRNAs as Non-Invasive Biomarkers in Brain Tumors.Diagnostics (Basel, Switzerland) · 2023Review
- Advances in transdermal siRNAs delivery: A review of current research progress.Non-coding RNA research · 2023Review
- The role of long non-coding RNAs in carbohydrate and fat metabolism in the liver.Non-coding RNA research · 2023Review
- The Long Non-Coding RNA ANRIL in Cancers.Cancers · 2023Review
- Long non-coding RNAs as promising biomarkers and therapeutic targets in cervical cancer.Non-coding RNA research · 2023Review
- The role of long non-coding RNAs in the development of adipose cells.Non-coding RNA research · 2023Review
- Studies on the role of non-coding RNAs in controlling the activity of T cells in asthma.Non-coding RNA research · 2023Review
- Regulation and mechanism of action of miRNAs on insulin resistance in skeletal muscles.Non-coding RNA research · 2023Review
- Exosomal non coding RNAs as a novel target for diabetes mellitus and its complications.Non-coding RNA research · 2023Review
- Role of miRNAs in vascular development.Non-coding RNA research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPituitary adenoma (PA) accounts for 10-15% of all intracranial neoplasms. Despite their benign nature, PA often shows invasive growth. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are a class of non-coding RNAs that play important roles in PA initiation and progression.
aimThe aim of this study was to find specific profiles of miR-200a and long non-coding RNA (lncRNA) antisense non-coding RNA in the INK4 locus (ANRIL) in PA based on a comparative study using Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) analyses of tumor tissue and plasma.
methodsPlasma and PA tissue samples were obtained from two groups of included patients (15 invasive and 15 non-invasive PA). In addition, plasma samples from patients with invasive PA have collected pre- and post-operation. Plasma and tissue samples subjected to qRT-PCR analyses for the expression levels of miR-200a and lncRNA ANRIL.
resultsThe expression levels of miR-200a and lncRNA ANRIL were increased in tissue samples patients with invasive PA than in the patients with non-invasive PA. In addition, the expression levels of circulating miR-200a and lncRNA ANRIL were increased in patients with invasive PA than in patients with non-invasive PA in the pre-operation period. However, the expression level of plasma circulating miR-200a and lncRNA ANRIL was decreased in patients with invasive PA in the post-operation period. Our results depicted a miR-200a and lncRNA ANRIL expression in tissue and plasma samples in the patients with invasive PA. In addition, Receiver Operating Characteristic (ROC) curve was used to evaluate the diagnostic value of these circulating miR-200a and lncRNA ANRIL.
conclusionThe expression of these tumor-associated ncRNAs has been elevated in the PAs. Therefore, miR-200a and lncRNA ANRIL represents as biomarkers for diagnosis and potential targets for novel invasive PA treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.